A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

About the study

The purpose of this study is to evaluate the long-term safety and efficacy of UCART19 administration to patients with advanced lymphoid leukemia.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Written informed consent obtained prior any study-specific procedure (patient or parent(s) or legal representative)
Patient dosed with UCART19 who completed or discontinued early from a sponsored or from any investigator-initiated study that tested UCART19, or patients who were administered UCART19 under a special access scheme (compassionate use);
Female patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners for a 12-month duration after the last UCART19 administration.

EXCLUSION CRITERIA

Exclusion Criteria:

- No exclusion criteria for this study

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Contition

Advanced Lymphoid Leukemia

Phase

Phase 1

Participants needed

Est. Completion Date

Feb 28, 2025

Treatment type

Interventional

Sponsor

Servier

ClinicalTrials.gov identifier

NCT02735083

Study number

CL1-68587-003